This might be referred to the impact of other predictors of outcome in DLBCL that might have been overlooked in our study (immunoblastic histology; molecular markers such as BCL2, c-myc, stromal signatures, gene expression profile subtypes) [24]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.